Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
Clinical trial NCT05173805 · UNKNOWN
Trial details
- NCT number
- NCT05173805
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-30
- Primary completion
- 2024-04-30
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.